A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment

Trial Profile

A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Masitinib (Primary) ; Imatinib
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Sponsors AB Science
  • Most Recent Events

    • 28 Jul 2018 The study has been discontinued in Spain.
    • 25 May 2018 This trial has been Discontinued in Greece (End date: 2018-05-30).
    • 15 Jun 2017 This trial has been suspended in Germany.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top